Learn More
PURPOSE The antibody-drug conjugate trastuzumab-DM1 (T-DM1) combines the biologic activity of trastuzumab with targeted delivery of a potent antimicrotubule agent, DM1, to human epidermal growth(More)
1052 Background: Bevacizumab with chemotherapy has shown improvement in progression-free survival (PFS) in MBC patients (pts) (Miller 2007; Miles 2008; Brufsky 2009; Robert, et al 2009). We examined(More)